Literature DB >> 8750719

Changes in the regulation of 5-hydroxytryptamine release by alpha2-adrenoceptors in the rat hippocampus after long-term desipramine treatment.

M Yoshioka1, M Matsumoto, R Numazawa, H Togashi, C B Smith, H Saito.   

Abstract

In vivo microdialysis was used to measure the effects of long-term treatment of rats with desipramine upon the regulation by alpha2-adrenoceptors of serotonin (5-hydroxytryptamine, 5-HT) release from the serotonergic neurons in the hippocampus. Rats were injected with saline or desipramine, 10 mg/kg, i.p., every 12 h for 14 days. When added to the perfusion solution, brimonidine, an alpha2-adrenoceptor agonist, significantly inhibited the K+-evoked release of 5-HT in the hippocampi of saline-treated, control rats. This action of brimonidine was prevented by pretreating the rats with idazoxan, an alpha2-adrenoceptor antagonist. Long-term desipramine treatment significantly reduced the inhibitory effect of brimonidine upon the K+-evoked 5-HT release. With long-term administration of desipramine, noradrenaline content in the hippocampi was significantly decreased as compared with that of the control rats, whereas the basal noradrenaline concentration in the dialysate was significantly increased. On the other hand, both the 5-HT content of the hippocampus and the basal 5-HT concentration in the dialysate were significantly increased. The present study suggests that long-term administration of desipramine causes a functional subsensitivity of the presynaptic alpha2-adrenoceptors that regulate serotonergic neuronal function in the rat hippocampus. It also supports the concept that changes in the sensitivity of alpha2-adrenoceptors that regulate neurotransmitter release play an important role in the mechanism of antidepressant drug action.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750719     DOI: 10.1016/0014-2999(95)00582-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.

Authors:  J Srinivasan; W J Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

2.  Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors.

Authors:  N Haddjeri; P Blier; C de Montigny
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

3.  Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study.

Authors:  Y Mateo; B Fernández-Pastor; J J Meana
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Chronic electroconvulsive shock and 5-HT autoreceptor activity in rat brain: an in vivo microdialysis study.

Authors:  E Gur; B Lerer; M E Newman
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy.

Authors:  Ouissame Mnie-Filali; Céline Faure; Laura Lambás-Señas; Mostafa El Mansari; Hassina Belblidia; Elise Gondard; Adeline Etiévant; Hélène Scarna; Anne Didier; Anne Berod; Pierre Blier; Nasser Haddjeri
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

6.  Norepinephrine-mediated regulation of 5HT1 receptor functioning in human platelets.

Authors:  M L Trincavelli; S Cuboni; M Montali; S Santaguida; A Lucacchini; C Martini
Journal:  Neurochem Res       Date:  2008-02-13       Impact factor: 3.996

7.  Opposing effects of α2- and β-adrenergic receptor stimulation on quiescent neural precursor cell activity and adult hippocampal neurogenesis.

Authors:  Dhanisha J Jhaveri; Ishira Nanavaty; Boris W Prosper; Swanand Marathe; Basma F A Husain; Steven G Kernie; Perry F Bartlett; Vidita A Vaidya
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.